← Back to Screener
Nkarta, Inc. Common Stock (NKTX)
Price$3.14
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)71.93%
Price vs S&P 500 (4W)5.95%
VGM Score79.44
Market Capitalization$232.52M
All Metrics
Book Value / Share (Quarterly)$4.00
P/TBV (Annual)0.35x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.24
Price vs S&P 500 (YTD)64.74%
EPS (TTM)$-1.35
10-Day Avg Trading Volume0.54M
EPS Excl Extra (TTM)$-1.35
EPS (Annual)$-1.60
ROI (Annual)-26.72%
Cash / Share (Quarterly)$3.22
ROA (Last FY)-21.75%
EBITD / Share (TTM)$-1.45
ROE (5Y Avg)-32.64%
Cash Flow / Share (Annual)$-1.26
P/B Ratio0.81x
P/B Ratio (Quarterly)0.53x
Net Income / Employee (Annual)$-1,009,300
ROA (TTM)-24.20%
EPS Incl Extra (Annual)$-1.60
Current Ratio (Annual)12.69x
Quick Ratio (Quarterly)12.66x
3-Month Avg Trading Volume0.79M
52-Week Price Return79.56%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$6.05
P/S Ratio (Annual)1937.69x
Asset Turnover (Annual)0.00x
52-Week High$3.65
EPS Excl Extra (Annual)$-1.60
CapEx CAGR (5Y)-30.61%
26-Week Price Return87.86%
Quick Ratio (Annual)12.52x
13-Week Price Return24.05%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)12.96x
Enterprise Value$205.17M
Book Value / Share Growth (5Y)-14.92%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-17566.67%
Cash / Share (Annual)$3.89
3-Month Return Std Dev86.98%
Net Income / Employee (TTM)$-925,300
ROE (Last FY)-26.72%
EPS Basic Excl Extra (Annual)$-1.60
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.35
ROI (TTM)-30.90%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$7.62
Price vs S&P 500 (52W)51.35%
Year-to-Date Return75.68%
5-Day Price Return7.26%
EPS Normalized (Annual)$-1.60
ROA (5Y Avg)-27.09%
Net Profit Margin (Annual)-17566.67%
Month-to-Date Return17.33%
Cash Flow / Share (TTM)$-2.41
EBITD / Share (Annual)$-1.75
Operating Margin (Annual)-19250.00%
ROI (5Y Avg)-32.64%
EPS Basic Excl Extra (TTM)$-1.35
P/TBV (Quarterly)0.43x
P/B Ratio (Annual)0.42x
Book Value / Share (Annual)$4.39
Price vs S&P 500 (13W)14.30%
Beta0.89x
Revenue / Share (TTM)$0.00
ROE (TTM)-30.90%
52-Week Low$1.63
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.37est. -0.38
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.15
4.15
4.25
4.27
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
NKTXNkarta, Inc. Common Stock | — | — | B | $3.14 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Nkarta is a clinical-stage biopharmaceutical company developing off-the-shelf allogeneic natural killer (NK) cell therapies for cancer treatment. The company combines proprietary NK cell expansion technology with engineered cell recognition capabilities to enhance therapeutic targeting and persistence. This approach aims to generate an abundant supply of engineered NK cells that can identify and eliminate cancer cells while triggering durable immune responses.